Insulin Delivery Devices Market Size By Product (Pumps {Tubed Pumps, Tubeless/Patch Pumps}, Pens {Reusable, Disposable}, Pen Needles {Standard, Safety}, Syringes), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, China, Japan, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Application Potential, Competitive Market Share & Forecast, 2019 – 2025

Published Date: Aug 2019 |    |  Report ID: GMI1649  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 156   |   Base Year: 2018




Summary Table of Contents Industry Coverage Methodology

Industry Trends

Global Insulin Delivery Devices Market size was valued over USD 12.9 billion in 2018 and is expected to witness more than 6.5% CAGR from 2019 to 2025.
 

UK Insulin Delivery Devices Market, By Product, 2018 & 2025 (USD Million)


UK Insulin Delivery Devices Market, By Product, 2018 & 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Diabetes is one of the leading causes of mortality worldwide. Rising number of diabetic patients and increasing obese population are the key factors stimulating the growth of the insulin delivery devices market. As per the International Diabetes Federation, the global diabetic population will reach upto 500 million by 2030. Growing geriatric population base, high adoption of sedentary lifestyle and growing awareness about diabetes treatment will further expand the insulin delivery device market size.
 

Rising awareness about advanced insulin delivery devices among diabetic patients will augment the demand for insulin delivering devices. The advance methods for insulin delivery include minimum invasiveness in an enhanced manner, reducing patients’ burden will positively affect the market growth over the upcoming period.
 

In recent years, funding in research towards development of advanced diabetic products has increased significantly, further boosting the industry growth. Continuous research update is been monitored in the insulin devices industry to offer optimal and cost-effective treatment to diabetic patients. For instance, the use of continues glucose monitoring (CGM) system and continuous subcutaneous insulin infusion (CSII) has increased widely owing to its improved clinical value, reduced risk of glycemia and improved hypoglycaemia control for type 1 and type 2 diabetic patients, positively affecting the diabetes treatment market growth.  However, high cost of insulin delivery devices and lack of insurance coverage in developing countries will negatively impact the market expansion in the near future. During the forecast period, risk and complications associated with the insulin delivery will also hamper the market growth.
 

Insulin Delivery Devices Market Report Coverage
Report Coverage Details
Base Year: 2018
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Pages: 156 Tables, Charts & Figures: 127
Geographies covered (16): U.S., Canada, Germany, UK, France, Spain, Italy, China, Japan, India, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Product and Region
Companies covered (10): Sanofi, Eli Lilly, Medtronic, Novo Nordisk, Insulet Corporation, Becton, Dickinson and Company (BD), Roche, Ypsomed, Wockhardt, B. Braun

Request 15% Free Customization on this Report
 

Insulin Delivery Devices Market, By Product

U.S. Insulin Delivery Device Market Share, By Pumps, 2018

U.S. Insulin Delivery Device Market Share, By Pumps, 2018

Get more details on this report - Request Free Sample PDF
 

Insulin pen needles market accounted for over USD 1.5 billion in 2018 and is projected to witness significant growth during the forecast period owing to accurate, simple and convenient way offered by insulin pen to deliver insulin rather using syringes and vials. In comparison to conventional methods, insulin pen needles offer portability, easy disposability, and time saving benefits. In recent times, insulin pen needles have become more user friendly and highly intuitive to use with little or no instructions.
 

Insulin syringes market is estimated to witness over 5% CAGR during the forecast period due to its increasing adoption rate. Market growth of the insulin syringes can be attributed to easy availability of the product, reusability, portability and cost-effective method of treatment for diabetic patients in low-income countries.
 

Insulin Delivery Devices Market, By Region

Asia Pacific Insulin Delivery Devices Market Share, By Country, 2025 (USD Million)

Asia Pacific Insulin Delivery Devices Market Share, By Country, 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Japan accounted over 35% revenue share of Asia Pacific insulin delivery devices industry in 2018. Increasing incidence of diabetes, growing geriatric population base and rise in adoption of sedentary lifestyle with urbanization will positively affect the market growth. According to the International Diabetes Federation (IDF), there were over 7.2 million cases of diabetes in the country in the year 2017 and is anticipated to grow with time. Rising awareness about advanced technology available for treatment of diabetes and favourable reimbursement policies are the major factors expanding the Japan insulin delivery industry.
 

Australia insulin delivery devices market will grow by 4.8% during the projected timeframe. Prevalence of diabetes is rising in Australia. According to a study, approximately 1.7 million Australians suffer from diabetes currently. Common risk factors such as unhealthy diet, lack of physical activity and obesity issues will contribute to the increasing cases of diabetes. High adoption of technologically advanced insulin delivery products, improved healthcare infrastructure and rising disposable income will support the business growth over the analysis timeline.
 

Competitive Market Share

Some of the key market players of global insulin delivery devices market are Sanofi, Becton, Dickinson and Company (BD), Eli Lilly, Novo Nordisk, Roche, Insulet Corporation, Medtronic, and Ypsomed. These companies are focusing on increasing investment in new product development to offer advanced insulin delivery devices to gain competitive advantage as well as increase the company’s product sales. Strategic alliance is also one of the major strategies adopted by these companies to consolidate their market position.
 

Recent industry developments:

  • In January 2019, Bigfoot Biomedical partnered with Eli Lilly to develop solutions for optimization of delivery and dosing of insulin using artificial intelligence. The partnership aimed at elevating the company’s position in the market by introduction of innovative products for diabetic patients.
     
  • In February 2019, Novo Nordisk entered into a partnership with Abbott to provide integrated digital solutions for diabetic patients using insulin pens. This strategic move aimed at optimizing diabetes management by enabling healthcare professionals and diabetic patients to generate more productive and meaningful outcomes.
     

Global Insulin Delivery Devices Industry Background

Insulin Delivery Devices Market Segmentation

Get more details on this report - Request Free Sample PDF
 

The discovery of insulin in 1920s marked a major development in the treatment process for the patients suffering from diabetes. Subsequently, the industry has witnessed rapid evolution by launch of various advanced insulin delivery devices such as insulin pens, insulin pumps, syringes and insulin pen needles, defining greatest discoveries in the medical field. The need for delivering insulin in a minimally invasive or non-invasive method is the foremost requirement of the diabetes treatment industry. The development in insulin delivery devices was followed by development of first insulin pen in 1985 by Novo Nordisk. This discovery was followed by refinements made by major market players by introducing more accurate and reusable insulin pens. For instance, Novo Nordisk introduced a pen device (HumaPen Memoir) capable of recording time and date of previous 16 injections, thereby reducing chances of error and enabling better memory function by providing more accurate information. Furthermore, with recent developments in continuous glucose monitors (CGM), combination of insulin pumps and CGM has marked significant evolution in the development of insulin delivery devices industry. The new generation CGM products offer precise results with improved glycaemic control in type-1 diabetic patients. Thus, advancements in diabetes management solutions will offer lucrative growth opportunities to insulin delivery devices industry players over the coming years.  


Buy Now

Single User: $5,150 Access to only 1 person; cannot be shared
Multi User: $7,150 Access for 2 to 5 users only within same department of one company
Enterprise User: $9,150 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Inquire Before Buying

Connect with our sales team

This site is protected by Trustwave's Trusted Commerce program Authorize.Net Merchant - Click to Verify BBB Rating - Click to Verify
Chat With Us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info. I Agree